Sales of Patanol, an antiallergic ophthalmic solution, which was launched in October 2006, also performed well. Income from the licensing-out of ...
Sales of Patanol, an antiallergic ophthalmic solution, which was launched in October 2006, also performed well. Income from the licensing-out of ...
Barr Laboratories recently submitted an abbreviated new drug application (ANDA) for generic Patanol with Paragraph IV certifications, prompting Alcon ...
Barr Pharma subsidiary Barr Labs confirms filing an application with a Paragraph IV Certification for Patanol Ophthalmic Solution, 0.1% Co confirms that its ...
N: Quote, Profile, Research) conjunctivitis drug, Patanol, following an Alcon suit that sought to prevent Barr from commercializing a generic version of the ...
WOODCLIFF LAKE, NJ — Barr Laboratories has initiated a challenge of patents listed by Alcon in connection with Alcon's Patanol, according to a press release ...
Barr filed its Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for a generic Patanol product with the US Food & Drug ...
Barr said it received notice from the US Food and Drug Administration that its abbreviated new drug application for a generic version of Patanol, ...
Patanase contains the same active ingredient as Pataday and Patanol, the company's other treatments for eye-related allergy symptoms. ...
Patanase contains the same active ingredient as Pataday and Patanol, the company's other treatments for eye-related allergy symptoms. ...